• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Moldova Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Moldova Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373257
  • January 2013
  • Region: Moldova
  • 72 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Profiles
  • Farmaco (Pharmaco)
  • Gedeon Richter
  • GlaxoSmithKline
  • Local Companies
  • Multinational Companies
  • MORE

BMI View:

Given the high level of reliance on out-of-pocket payments, the growth of the Moldova's pharmaceutical market is expected to be shaped by the prevailing economic conditions, both at home and abroad, on account of the importance of remittances to the country's GDP. For 2012, we expect the market's value to increase at a local currency rate of 6.7%, although this will translate into negative US dollar growth, on the back of a weak leu.

Headline Expenditure Projections:

- Pharmaceuticals: MDL2.47bn (US$211mn) in 2011 to MDL2.64bn (US$204mn) in 2012;
+6.7% in local currency terms and -3.0% in US dollar terms. Forecast unchanged from Q412.

- Healthcare: MDL9.06bn (US$773mn) in 2011 to MDL9.64bn (US$747mn) in 2012; +6.4% in local currency terms and -3.3% in US dollar terms. Forecast unchanged from Q412.

- Medical devices: MDL669mn (US$57mn) in 2011 to MDL735mn (US$57mn) in 2012; +9.8
%in local currency terms and -0.2% in US dollar terms. Forecast unchanged from Q412.

Risk/Reward Rating:

Moldova's Pharmaceutical Risk/Reward Rating (RRR) score, which assesses the country's attractiveness to multinational drugmakers, remains READ MORE >

FEATURED COMPANIES

  • Company Profiles
  • Farmaco (Pharmaco)
  • Gedeon Richter
  • GlaxoSmithKline
  • Local Companies
  • Multinational Companies
  • MORE

Executive Summary 5

SWOT Analysis 7

Moldova Pharmaceuticals And Healthcare Industry SWOT 7

Pharmaceutical Risk/Reward Ratings 8
Table: Emerging Europe Pharmaceutical And Healthcare Risk/Reward Ratings, Q113 8

Risks 9

Moldova - Market Summary 11

Regulatory Regime 12

Intellectual Property Rights 12

Marketing Authorisation 13

Advertising of Medicines 13

Counterfeit Pharmaceuticals 14

Pricing Regime 14

Reimbursement Regime 15

International Trade Agreements 16

Industry Developments 18

Epidemiology 18
Table: 10 Most Frequent Causes of Death 19
Table: Leading Causes Of Morbidity, % Of Total Disease Burden 20

Communicable Diseases 20

Healthcare Sector 21

Healthcare Financing 22
Table: Public Healthcare Expenditure, 2006-2011 22

Primary Care 24

Secondary Care 24
Table: Physicians And Hospital Beds In Moldova, 2003-2011 25

Compulsory Health Insurance 25

Health Insurance Developments 26

Research & Development 27

Medical Devices 28

Industry Forecast Scenario 30

Pharmaceutical Market Forecast 30
Table: Pharmaceutical Sales Indicators 2008-2016 32

Healthcare Market Forecast 34
Table: General Government Budget, 2008-2016 35
Table: Healthcare Expenditure Indicators 2008-2016 35
Table: Healthcare Governmental Indicators 2008-2016 36
Table: Healthcare Private Indicators 2008-2016 36

Key Growth Factors - Macroeconomic 38

Prescription Drug Market Forecast 39
Table: Prescription Drug Sales Indicators 2008-2016 40

Patented Drug Market Forecast 41
Table: Patented Drug Market Indicators 2008-2016 41

Generic Drug Market Forecast 43
Table: Generic Drug Sales Indicators 2008-2016 44

OTC Medicine Market Forecast 45
Table: OTC Medicine Sales Indicators 2008-2016 46

Pharmaceutical Trade Forecast 46
Table: Exports And Imports Indicators 2008-2016 47

Medical Device Market Forecast 49
Table: Medical Device Sales Indicators 2008-2016 49

Key Risks To BMI's Forecasts 51

Competitive Landscape 52

Pharmaceutical Industry 52

Domestic Industry 53

Foreign Industry 53

Recent Pharmaceutical Industry Developments 54

Pharmaceutical Wholesale 54

Pharmaceutical Retail 55

Company Profiles 56

Local Companies 56

Farmaco (Pharmaco) 56

Top Pharm 58

Multinational Companies 59

Gedeon Richter 59

GlaxoSmithKline 61

Novartis (Sandoz) 63

Sanofi 64

Pfizer 65

Glossary 66

BMI Methodology 68

How We Generate Our Pharmaceutical Industry Forecasts 68

Pharmaceuticals Business Environment Ratings 69

Risk/Reward Ratings Methodology 69

Ratings Overview 69
Table: Pharmaceutical Business Environment Indicators 70

Weighting 71
Table: Weighting Of Components 71

Sources 71

Company Profiles
Local Companies
Farmaco (Pharmaco)
Top Pharm
Multinational Companies
Gedeon Richter
GlaxoSmithKline
Novartis (Sandoz)
Sanofi
Pfizer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos